These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 10229429)

  • 1. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review.
    Ruof J; Stucki G
    J Rheumatol; 1999 Apr; 26(4):966-70. PubMed ID: 10229429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
    Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
    Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.
    Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
    J Rheumatol; 1999 Apr; 26(4):980-4. PubMed ID: 10229432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis.
    Ward MM
    J Rheumatol; 2004 May; 31(5):884-95. PubMed ID: 15124246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists.
    Paulus HE; Ramos B; Wong WK; Ahmed A; Bulpitt K; Park G; Sterz M; Clements P
    J Rheumatol; 1999 Nov; 26(11):2324-31. PubMed ID: 10555885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein: a marker for disease activity in ankylosing spondylitis and Reiter's syndrome.
    Nashel DJ; Petrone DL; Ulmer CC; Sliwinski AJ
    J Rheumatol; 1986 Apr; 13(2):364-7. PubMed ID: 3723498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis.
    van der Heijde D; Calin A; Dougados M; Khan MA; van der Linden S; Bellamy N
    J Rheumatol; 1999 Apr; 26(4):951-4. PubMed ID: 10229426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The value of erythrocyte sedimentation rate and C-reactive protein in evaluating disease activity in ankylosing spondylitis].
    Liu B; Guo CY; Liu WQ; Wu N; Xing Q
    Zhonghua Nei Ke Za Zhi; 2005 Aug; 44(8):566-9. PubMed ID: 16194404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy.
    Maksymowych WP; Lambert R; Jhangri GS; Leclercq S; Chiu P; Wong B; Aaron S; Russell AS
    J Rheumatol; 2001 Jan; 28(1):144-55. PubMed ID: 11196517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis.
    van Denderen JC; van der Horst-Bruinsma I; Bezemer PD; Dijkmans BA
    J Rheumatol; 2003 Jul; 30(7):1558-60. PubMed ID: 12858458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
    Cantini F; Salvarani C; Olivieri I; Macchioni L; Ranzi A; Niccoli L; Padula A; Boiardi L
    Semin Arthritis Rheum; 2000 Aug; 30(1):17-24. PubMed ID: 10966209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity.
    Stone M; Fortin PR; Pacheco-Tena C; Inman RD
    J Rheumatol; 2003 Oct; 30(10):2112-22. PubMed ID: 14528503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble and tissue biomarkers in ankylosing spondylitis.
    de Vlam K
    Best Pract Res Clin Rheumatol; 2010 Oct; 24(5):671-82. PubMed ID: 21035087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.